October 26, 2020 
Revive Expects To Complete Phase 3 Interim Analysis In December On Bucillamine In Treatment of COVID-19
Revive Therapeutics (CSE: RVV) provided an update on the status of its ongoing phase three clinical trials for the evaluation of Bucillamine as a treatment for mild to moderate COVID-19 this morning. Clinical sites have been committed to in connection with the evaluation, with interim analysis expected to be completed on 200 patients by the end of December.
Ten clinical sites are currently committed to across several states, including Florida, Texas, Nevada and California. The sites are currently estimated to have a total of over 200 patients complete the study by the end of December for the interim analysis.
This analysis will enable the company to determine the best performing dosage of Bucillamine in the treatment of COVID-19, which will be used for the remainder of the trial and future complementary studies for more severe cases. Currently, the company is testing dosages of 100 mg, 200 mg, and a placebo to determine the ideal amount of Bucillamine for treatment of the disease.
“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3mclinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we aremconfident that our targets will be achieved to support the potential FDA approval andmcommercialization of Bucillamine for the treatment of the virus.”
Michael Frank, CEO of Revive Therapeutics
Additionally, a recent report published has provided further validation for the use of Bucillamine as a treatment for the disease. The publication was focused on the treatment of the potential of N-acetyl-cysteine, or NAC, in the treatment of COVID. The drug has been shown to significantly reduce clinical symptoms of the disease in respiratory viral infections of both animals and humans, which is said to be primarily through the donation of thiols. Bucillamine has been shown to be 16 times more potent as thiol donor than NAC